Search

Your search keyword '"Brunner-La Rocca H"' showing total 269 results
Start Over Author "Brunner-La Rocca H"
Sorry, I don't understand your search. ×
269 results on '"Brunner-La Rocca H"'

2. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Author

Packer, M, Anker, S, Butler, J, Filippatos, G, Pocock, S, Zannad, F, Ferreira, JP, Brueckmann, M, George, J, Jamal, W, Welty, FK, Palmer, M, Clayton, T, Parhofer, KG, Pedersen, TR, Greenberg, B, Konstam, MA, Lees, KR, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, J, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Zhang, J, Spinar, J, Seronde, M-F, Boehm, M, Merkely, B, Chopra, V, Senni, M, Taddi, S, Tsutsui, H, Choi, D-J, Chuquiure, E, La Rocca, HPB, Ponikowski, P, Juanatey, JRG, Squire, I, Januzzi, J, Pina, I, Bernstein, R, Cheung, A, Green, J, Kaul, S, Lam, C, Lip, G, Marx, N, McCullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Shah, S, Wanner, C, Aizenberg, D, Cartasegna, L, Colombo Berra, F, Colombo, H, Fernandez Moutin, M, Glenny, J, Alvarez Lorio, C, Anauch, D, Campos, R, Facta, A, Fernandez, A, Ahuad Guerrero, R, Lobo Márquez, L, Leon de la Fuente, RA, Mansilla, M, Hominal, M, Hasbani, E, Najenson, M, Moises Azize, G, Luquez, H, Guzman, L, Sessa, H, Amuchástegui, M, Salomone, O, Perna, E, Piskorz, D, Sicer, M, Perez de Arenaza, D, Zaidman, C, Nani, S, Poy, C, Resk, J, Villarreal, R, Majul, C, Smith Casabella, T, Sassone, S, Liberman, A, Carnero, G, Caccavo, A, Berli, M, Budassi, N, Bono, J, Alvarisqueta, A, Amerena, J, Kostner, K, Hamilton, A, Begg, A, Beltrame, J, Colquhoun, D, Gordon, G, Sverdlov, A, Vaddadi, G, Wong, J, Coller, J, Prior, D, Friart, A, Leone, A, Vervoort, G, Timmermans, P, Troisfontaines, P, Franssen, C, Sarens, T, Vandekerckhove, H, Van De Borne, P, Chenot, F, De Sutter, J, De Vuyst, E, Debonnaire, P, Dupont, M, Pereira Dutra, O, Canani, LH, Vieira Moreira, MdC, de Souza, W, Backes, LM, Maia, L, De Souza Paolino, B, Manenti, ER, Saporito, W, Villaça Guimarães Filho, F, Franco Hirakawa, T, Saliba, LA, Neuenschwander, FC, de Freitas Zerbini, CA, Gonçalves, G, Gonçalves Mello, Y, Ascenção de Souza, J, Beck da Silva Neto, L, Bocchi, EA, Da Silveira, J, de Moura Xavier Moraes Junior, JB, de Souza Neto, JD, Hernandes, M, Finimundi, HC, Sampaio, CR, Vasconcellos, E, Neves Mancuso, FJ, Noya Rabelo, MM, Rodrigues Bacci, M, Santos, F, Vidotti, M, Simões, MV, Gomes, FL, Vieira Nascimento, C, Precoma, D, Helfenstein Fonseca, FA, Ribas Fortes, JA, Leães, PE, Campos de Albuquerque, D, Kerr Saraiva, JF, Rassi, S, Alves da Costa, FA, Reis, G, Zieroth, S, Dion, D, Savard, D, Bourgeois, R, Constance, C, Anderson, K, Leblanc, M-H, Yung, D, Swiggum, E, Pliamm, L, Pesant, Y, Tyrrell, B, Huynh, T, Spiegelman, J, Lavoie, J-P, Hartleib, M, Bhargava, R, Straatman, L, Virani, S, Costa-Vitali, A, Hill, L, Heffernan, M, Khaykin, Y, Ricci, J, Senaratne, M, Zhai, A, Lubelsky, B, Toma, M, Yao, L, McKelvie, R, Noronha, L, Babapulle, M, Pandey, A, Curnew, G, Lavoie, A, Berlingieri, J, Kouz, S, Lonn, E, Chehayeb, R, Zheng, Y, Sun, Y, Cui, H, Fan, Z, Han, X, Jiang, X, Tang, Q, Zhou, J, Zheng, Z, Zhang, X, Zhang, N, Zhang, Y, Shen, A, Yu, J, Ye, J, Yao, Y, Yan, J, Xu, X, Wang, Z, Ma, J, Li, Y, Li, S, Lu, S, Kong, X, Song, Y, Yang, G, Yao, Z, Pan, Y, Guo, X, Sun, Z, Dong, Y, Zhu, J, Peng, D, Yuan, Z, Lin, J, Yin, Y, Jerabek, O, Burianova, H, Fiala, T, Hubac, J, Ludka, O, Monhart, Z, Vodnansky, P, Zeman, K, Foldyna, D, Krupicka, J, Podpera, I, Busak, L, Radvan, M, Vomacka, Z, Prosecky, R, Cifkova, R, Durdil, V, Vesely, J, Vaclavik, J, Cervinka, P, Linhart, A, Brabec, T, Miklik, R, Bourhaial, H, Olbrich, H-G, Genth-Zotz, S, Kemala, E, Lemke, B, Böhm, M, Schellong, S, Rieker, W, Heitzer, T, Ince, H, Faghih, M, Birkenfeld, A, Begemann, A, Ghanem, A, Ujeyl, A, von Haehling, S, Dorsel, T, Bauersachs, J, Prull, M, Weidemann, F, Darius, H, Nickenig, G, Wilke, A, Sauter, J, Rauch-Kroehnert, U, Frey, N, Schulze, CP, König, W, Maier, L, Menzel, F, Proskynitopoulos, N, Ebert, H-H, Sarnighausen, H-E, Düngen, H-D, Licka, M, Stellbrink, C, Winkelmann, B, Menck, N, López-Sendón, JL, de la Fuente Galán, L, Delgado Jiménez, JF, Manito Lorite, N, Pérez de Juan Romero, M, Galve Basilio, E, Cereto Castro, F, González Juanatey, JR, Gómez, JJ, Sanmartín Fernández, M, Garcia-Moll Marimon, X, Pascual Figal, D, Bover Freire, R, Bonnefoy Cudraz, E, Jobbe Duval, A, Tomasevic, D, Habib, G, Isnard, R, Picard, F, Khanoyan, P, Dubois-Rande, J-L, Galinier, M, Roubille, F, Alexandre, J, Babuty, D, Delarche, N, Berneau, J-B, Girerd, N, Saxena, M, Rosano, G, Yousef, Z, Clifford, C, Arden, C, Bakhai, A, Boos, C, Jenkins, G, Travill, C, Price, D, Koenyves, L, Lakatos, F, Matoltsy, A, Noori, E, Zilahi, Z, Andrassy, P, Kancz, S, Simon, G, Sydo, T, Vorobcsuk, A, Kiss, RG, Toth, K, Szakal, I, Nagy, L, Barany, T, Nagy, A, Szolnoki, E, Chopra, VK, Mandal, S, Rastogi, V, Shah, B, Mullasari, A, Shankar, J, Mehta, V, Oomman, A, Kaul, U, Komarlu, S, Kahali, D, Bhagwat, A, Vijan, V, Ghaisas, NK, Mehta, A, Kashyap, J, Kothari, Y, TaddeI, S, Scherillo, M, Zacà, V, Genovese, S, Salvioni, A, Fucili, A, Fedele, F, Cosmi, F, Volpe, M, Mazzone, C, Esposito, G, Doi, M, Yamamoto, H, Sakagami, S, Oishi, S, Yasaka, Y, Tsuboi, H, Fujino, Y, Matsuoka, S, Watanabe, Y, Himi, T, Ide, T, Ichikawa, M, Kijima, Y, Koga, T, Yuda, S, Fukui, K, Kubota, T, Manita, M, Fujinaga, H, Matsumura, T, Fukumoto, Y, Kato, R, Kawai, Y, Hiasa, G, Kazatani, Y, Mori, M, Ogimoto, A, Inoko, M, Oguri, M, Kinoshita, M, Okuhara, K, Watanabe, N, Ono, Y, Otomo, K, Sato, Y, Matsunaga, T, Takaishi, A, Miyagi, N, Uehara, H, Takaishi, H, Urata, H, Kataoka, T, Matsubara, H, Matsumoto, T, Suzuki, T, Takahashi, N, Imamaki, M, Yoshitama, T, Saito, T, Sekino, H, Furutani, Y, Koda, M, Shinozaki, T, Hirabayashi, K, Tsunoda, R, Yonezawa, K, Hori, H, Yagi, M, Arikawa, M, Hashizume, T, Ishiki, R, Koizumi, T, Nakayama, K, Taguchi, S, Nanasato, M, Yoshida, Y, Tsujiyama, S, Nakamura, T, Oku, K, Shimizu, M, Suwa, M, Momiyama, Y, Sugiyama, H, Kobayashi, K, Inoue, S, Kadokami, T, Maeno, K, Kawamitsu, K, Maruyama, Y, Nakata, A, Shibata, T, Wada, A, Cho, H-J, Na, JO, Yoo, B-S, Choi, J-O, Hong, SK, Shin, J-H, Cho, M-C, Han, SH, Jeong, J-O, Kim, J-J, Kang, SM, Kim, D-S, Kim, MH, Llamas Esperon, G, Illescas Díaz, J, Fajardo Campos, P, Almeida Alvarado, J, Bazzoni Ruiz, A, Echeverri Rico, J, Lopez Alcocer, I, Valle Molina, L, Hernandez Herrera, C, Calvo Vargas, C, Padilla Padilla, FG, Rodriguez Briones, I, Chuquiure Valenzuela, EJJR, Aguilera Real, ME, Carrillo Calvillo, J, Alpizar Salazar, M, Cervantes Escárcega, JL, Velasco Sanchez, R, Al - Windy, N, van Heerebeek, L, Bellersen, L, Brunner-La Rocca, H-P, Post, J, Linssen, GCM, van de Wetering, M, Peters, R, van Stralen, R, Groutars, R, Smits, P, Yilmaz, A, Kok, WEM, Van der Meer, P, Dijkmans, P, Troquay, R, van Alem, AP, Van de Wal, R, Handoko, L, Westendorp, ICD, van Bergen, PFMM, Rensing, BJWM, Hoogslag, P, Kietselaer, B, Kragten, JA, den Hartog, FR, Alings, A, Danilowicz-Szymanowicz, L, Raczak, G, Piesiewicz, W, Zmuda, W, Kus, W, Podolec, P, Musial, W, Drelich, G, Kania, G, Miekus, P, Mazur, S, Janik, A, Spyra, J, Peruga, J, Balsam, P, Krakowiak, B, Szachniewicz, J, Ginel, M, Grzybowski, J, Chrustowski, W, Wojewoda, P, Kalinka, A, Zurakowski, A, Koc, R, Debinski, M, Fil, W, Kujawiak, M, Forys, J, Kasprzak, M, Krol, M, Michalski, P, Mirek-Bryniarska, E, Radwan, K, Skonieczny, G, Stania, K, Skoczylas, G, Madej, A, Jurowiecki, J, Firek, B, Wozakowska-Kaplon, B, Cymerman, K, Neutel, J, Adams, K, Balfour, P, Deswal, A, Djamson, A, Duncan, P, Hong, M, Murray, C, Rinde-Hoffman, D, Woodhouse, S, MacNevin, R, Rama, B, Broome-Webster, C, Kindsvater, S, Abramov, D, Barettella, M, Pinney, S, Herre, J, Cohen, A, Vora, K, Challappa, K, West, S, Baum, S, Cox, J, Jani, S, Karim, A, Akhtar, A, Quintana, O, Paukman, L, Goldberg, R, Bhatti, Z, Budoff, M, Bush, E, Potler, A, Delgado, R, Ellis, B, Dy, J, Fialkow, J, Sangrigoli, R, Ferdinand, K, East, C, Falkowski, S, Donahoe, S, Ebrahimi, R, Kline, G, Harris, B, Khouzam, R, Jaffrani, N, Jarmukli, N, Kazemi, N, Koren, M, Friedman, K, Herzog, W, Silva Enciso, J, Cheung, D, Grover-McKay, M, Hauptman, P, Mikhalkova, D, Hegde, V, Hodsden, J, Khouri, S, McGrew, F, Littlefield, R, Bradley, P, McLaurin, B, Lupovitch, S, Labin, I, Rao, V, Leithe, M, Lesko, M, Lewis, N, Lombardo, D, Mahal, S, Malhotra, V, Dauber, I, Banerjee, A, Needell, J, Miller, G, Paladino, L, Munuswamy, K, Nanna, M, McMillan, E, Mumma, M, Napoli, M, Nelson, W, O'Brien, T, Adlakha, A, Onwuanyi, A, Serota, H, Schmedtje, J, Paraschos, A, Potu, R, Sai-Sudhakar, C, Saltzberg, M, Sauer, A, Shah, P, Skopicki, H, Bui, H, Carr, K, Stevens, G, Tahirkheli, N, Tallaj, J, Yousuf, K, Trichon, B, Welker, J, Tolerico, P, Vest, A, Vivo, R, Wang, X, Abadier, R, Dunlap, S, Weintraub, N, Malik, A, Kotha, P, Zaha, V, Kim, G, Uriel, N, Greene, T, Salacata, A, Arora, R, Gazmuri, R, Kobayashi, J, Iteld, B, Vijayakrishnan, R, Dab, R, Mirza, Z, Marques, V, Nallasivan, M, Bensimhon, D, Peart, B, Saint-Jacques, H, Barringhaus, K, Contreras, J, Gupta, A, Koneru, S, Nguyen, V, Verma, Subodh, Dhingra, Nitish K, Butler, Javed, Anker, Stefan D, Ferreira, Joao Pedro, Filippatos, Gerasimos, Januzzi, James L, Lam, Carolyn S P, Sattar, Naveed, Peil, Barbara, Nordaby, Matias, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, and Packer, Milton

Published
2022
Full Text
View/download PDF

4. Standardised assessment of evidence supporting the adoption of mobile health solutions: A Clinical Consensus Statement of the ESC Regulatory Affairs Committee

Author

Caiani, E G, primary, Kemps, H, additional, Hoogendoorn, P, additional, Asteggiano, R, additional, Böhm, A, additional, Borregaard, B, additional, Boriani, G, additional, Brunner La Rocca, H P, additional, Casado-Arroyo, R, additional, Castelletti, S, additional, Christodorescu, R, additional, Cowie, M R, additional, Dendale, P, additional, Dunn, F, additional, Fraser, A G, additional, Lane, D A, additional, Locati, E T, additional, Małaczyńska-Rajpold, K, additional, Merșa, C, additional, Neubeck, L, additional, Parati, G, additional, Plummer, C, additional, Rosano, G, additional, Scherrenberg, M, additional, Smirthwaite, A, additional, and Szymanski, P, additional

Published
2024
Full Text
View/download PDF

5. Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial

Author

Clephas, P R D, primary, Zwartkruis, V W, additional, Malgie, J, additional, van Gent, M W F, additional, Brunner-La Rocca, H P, additional, Szymanski, M K, additional, van Halm, V P, additional, Handoko, M L, additional, Kok, W, additional, Asselbergs, F W, additional, van Kimmenade, R, additional, Manintveld, O, additional, van Mieghem, N M D A, additional, Beeres, S L M A, additional, Post, M C, additional, Borleffs, C J W, additional, Tukkie, R, additional, Mosterd, A, additional, Linssen, G C M, additional, Spee, R F, additional, Emans, M E, additional, Smilde, T D J, additional, van Ramshorst, J, additional, Kirchhof, C, additional, Feenema–Aardema, F, additional, da Fonseca, C A, additional, van den Heuve, M, additional, Hazeleger, R, additional, van Eck, M, additional, van Heerebeek, L, additional, Boersma, H, additional, Rienstra, M, additional, de Boer, R A, additional, and Brugts, J J, additional

Published
2024
Full Text
View/download PDF

7. Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial

Author

Team Medisch, Circulatory Health, Clephas, P R D, Zwartkruis, V W, Malgie, J, van Gent, M W F, Brunner-La Rocca, H P, Szymanski, M K, van Halm, V P, Handoko, M L, Kok, W, Asselbergs, F W, van Kimmenade, R, Manintveld, O, van Mieghem, N M D A, Beeres, S L M A, Post, M C, Borleffs, C J W, Tukkie, R, Mosterd, A, Linssen, G C M, Spee, R F, Emans, M E, Smilde, T D J, van Ramshorst, J, Kirchhof, C, Feenema-Aardema, F, da Fonseca, C A, van den Heuve, M, Hazeleger, R, van Eck, M, van Heerebeek, L, Boersma, H, Rienstra, M, de Boer, R A, Brugts, J J, Team Medisch, Circulatory Health, Clephas, P R D, Zwartkruis, V W, Malgie, J, van Gent, M W F, Brunner-La Rocca, H P, Szymanski, M K, van Halm, V P, Handoko, M L, Kok, W, Asselbergs, F W, van Kimmenade, R, Manintveld, O, van Mieghem, N M D A, Beeres, S L M A, Post, M C, Borleffs, C J W, Tukkie, R, Mosterd, A, Linssen, G C M, Spee, R F, Emans, M E, Smilde, T D J, van Ramshorst, J, Kirchhof, C, Feenema-Aardema, F, da Fonseca, C A, van den Heuve, M, Hazeleger, R, van Eck, M, van Heerebeek, L, Boersma, H, Rienstra, M, de Boer, R A, and Brugts, J J

Published
2024

8. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial

Author

Brugts, J. J., Veenis, J. F., Radhoe, S. P., Linssen, G. C. M., van Gent, M., Borleffs, C. J. W., van Ramshorst, J., van Pol, P., Tukkie, R., Spee, R. F., Emans, M. E., Kok, W., van Halm, V., Handoko, L., Beeres, S. L. M. A., Post, M. C., Boersma, E., Lenzen, M. J., Manintveld, O. C., Koffijberg, H., van Baal, P., Versteegh, M., Smilde, T. D., van Heerebeek, L., Rienstra, M., Mosterd, A., Delnoy, P. P. H., Asselbergs, F. W., Brunner-La Rocca, H. P., and de Boer, R. A.

Published
2020
Full Text
View/download PDF

19. Cardiac dysfunction in relation to vascular brain injury, cognitive impairment and depressive symptoms; The Heart-Brain Connection Study

Author

Amier, R P, primary, Marcks, N, additional, Leeuwis, A E, additional, Nijveldt, R, additional, Biessels, G J, additional, Kappelle, L J, additional, Van Oostenbrugge, R J, additional, Van Der Geest, R J, additional, Bots, M L, additional, Niessen, W J, additional, De Bresser, J, additional, Mooijaart, S P, additional, Van Der Flier, W M, additional, Brunner-La Rocca, H P, additional, and Van Rossum, A C, additional

Published
2022
Full Text
View/download PDF

25. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Author

Verma, Subodh, primary, Dhingra, Nitish K, additional, Butler, Javed, additional, Anker, Stefan D, additional, Ferreira, Joao Pedro, additional, Filippatos, Gerasimos, additional, Januzzi, James L, additional, Lam, Carolyn S P, additional, Sattar, Naveed, additional, Peil, Barbara, additional, Nordaby, Matias, additional, Brueckmann, Martina, additional, Pocock, Stuart J, additional, Zannad, Faiez, additional, Packer, Milton, additional, Packer, M, additional, Anker, S, additional, Butler, J, additional, Filippatos, G, additional, Pocock, S, additional, Zannad, F, additional, Ferreira, JP, additional, Brueckmann, M, additional, George, J, additional, Jamal, W, additional, Welty, FK, additional, Palmer, M, additional, Clayton, T, additional, Parhofer, KG, additional, Pedersen, TR, additional, Greenberg, B, additional, Konstam, MA, additional, Lees, KR, additional, Carson, P, additional, Doehner, W, additional, Miller, A, additional, Haas, M, additional, Pehrson, S, additional, Komajda, M, additional, Anand, I, additional, Teerlink, J, additional, Rabinstein, A, additional, Steiner, T, additional, Kamel, H, additional, Tsivgoulis, G, additional, Lewis, J, additional, Freston, J, additional, Kaplowitz, N, additional, Mann, J, additional, Petrie, J, additional, Perrone, S, additional, Nicholls, S, additional, Janssens, S, additional, Bocchi, E, additional, Giannetti, N, additional, Verma, S, additional, Zhang, J, additional, Spinar, J, additional, Seronde, M-F, additional, Boehm, M, additional, Merkely, B, additional, Chopra, V, additional, Senni, M, additional, Taddi, S, additional, Tsutsui, H, additional, Choi, D-J, additional, Chuquiure, E, additional, La Rocca, HPB, additional, Ponikowski, P, additional, Juanatey, JRG, additional, Squire, I, additional, Januzzi, J, additional, Pina, I, additional, Bernstein, R, additional, Cheung, A, additional, Green, J, additional, Kaul, S, additional, Lam, C, additional, Lip, G, additional, Marx, N, additional, McCullough, P, additional, Mehta, C, additional, Rosenstock, J, additional, Sattar, N, additional, Scirica, B, additional, Shah, S, additional, Wanner, C, additional, Aizenberg, D, additional, Cartasegna, L, additional, Colombo Berra, F, additional, Colombo, H, additional, Fernandez Moutin, M, additional, Glenny, J, additional, Alvarez Lorio, C, additional, Anauch, D, additional, Campos, R, additional, Facta, A, additional, Fernandez, A, additional, Ahuad Guerrero, R, additional, Lobo Márquez, L, additional, Leon de la Fuente, RA, additional, Mansilla, M, additional, Hominal, M, additional, Hasbani, E, additional, Najenson, M, additional, Moises Azize, G, additional, Luquez, H, additional, Guzman, L, additional, Sessa, H, additional, Amuchástegui, M, additional, Salomone, O, additional, Perna, E, additional, Piskorz, D, additional, Sicer, M, additional, Perez de Arenaza, D, additional, Zaidman, C, additional, Nani, S, additional, Poy, C, additional, Resk, J, additional, Villarreal, R, additional, Majul, C, additional, Smith Casabella, T, additional, Sassone, S, additional, Liberman, A, additional, Carnero, G, additional, Caccavo, A, additional, Berli, M, additional, Budassi, N, additional, Bono, J, additional, Alvarisqueta, A, additional, Amerena, J, additional, Kostner, K, additional, Hamilton, A, additional, Begg, A, additional, Beltrame, J, additional, Colquhoun, D, additional, Gordon, G, additional, Sverdlov, A, additional, Vaddadi, G, additional, Wong, J, additional, Coller, J, additional, Prior, D, additional, Friart, A, additional, Leone, A, additional, Vervoort, G, additional, Timmermans, P, additional, Troisfontaines, P, additional, Franssen, C, additional, Sarens, T, additional, Vandekerckhove, H, additional, Van De Borne, P, additional, Chenot, F, additional, De Sutter, J, additional, De Vuyst, E, additional, Debonnaire, P, additional, Dupont, M, additional, Pereira Dutra, O, additional, Canani, LH, additional, Vieira Moreira, MdC, additional, de Souza, W, additional, Backes, LM, additional, Maia, L, additional, De Souza Paolino, B, additional, Manenti, ER, additional, Saporito, W, additional, Villaça Guimarães Filho, F, additional, Franco Hirakawa, T, additional, Saliba, LA, additional, Neuenschwander, FC, additional, de Freitas Zerbini, CA, additional, Gonçalves, G, additional, Gonçalves Mello, Y, additional, Ascenção de Souza, J, additional, Beck da Silva Neto, L, additional, Bocchi, EA, additional, Da Silveira, J, additional, de Moura Xavier Moraes Junior, JB, additional, de Souza Neto, JD, additional, Hernandes, M, additional, Finimundi, HC, additional, Sampaio, CR, additional, Vasconcellos, E, additional, Neves Mancuso, FJ, additional, Noya Rabelo, MM, additional, Rodrigues Bacci, M, additional, Santos, F, additional, Vidotti, M, additional, Simões, MV, additional, Gomes, FL, additional, Vieira Nascimento, C, additional, Precoma, D, additional, Helfenstein Fonseca, FA, additional, Ribas Fortes, JA, additional, Leães, PE, additional, Campos de Albuquerque, D, additional, Kerr Saraiva, JF, additional, Rassi, S, additional, Alves da Costa, FA, additional, Reis, G, additional, Zieroth, S, additional, Dion, D, additional, Savard, D, additional, Bourgeois, R, additional, Constance, C, additional, Anderson, K, additional, Leblanc, M-H, additional, Yung, D, additional, Swiggum, E, additional, Pliamm, L, additional, Pesant, Y, additional, Tyrrell, B, additional, Huynh, T, additional, Spiegelman, J, additional, Lavoie, J-P, additional, Hartleib, M, additional, Bhargava, R, additional, Straatman, L, additional, Virani, S, additional, Costa-Vitali, A, additional, Hill, L, additional, Heffernan, M, additional, Khaykin, Y, additional, Ricci, J, additional, Senaratne, M, additional, Zhai, A, additional, Lubelsky, B, additional, Toma, M, additional, Yao, L, additional, McKelvie, R, additional, Noronha, L, additional, Babapulle, M, additional, Pandey, A, additional, Curnew, G, additional, Lavoie, A, additional, Berlingieri, J, additional, Kouz, S, additional, Lonn, E, additional, Chehayeb, R, additional, Zheng, Y, additional, Sun, Y, additional, Cui, H, additional, Fan, Z, additional, Han, X, additional, Jiang, X, additional, Tang, Q, additional, Zhou, J, additional, Zheng, Z, additional, Zhang, X, additional, Zhang, N, additional, Zhang, Y, additional, Shen, A, additional, Yu, J, additional, Ye, J, additional, Yao, Y, additional, Yan, J, additional, Xu, X, additional, Wang, Z, additional, Ma, J, additional, Li, Y, additional, Li, S, additional, Lu, S, additional, Kong, X, additional, Song, Y, additional, Yang, G, additional, Yao, Z, additional, Pan, Y, additional, Guo, X, additional, Sun, Z, additional, Dong, Y, additional, Zhu, J, additional, Peng, D, additional, Yuan, Z, additional, Lin, J, additional, Yin, Y, additional, Jerabek, O, additional, Burianova, H, additional, Fiala, T, additional, Hubac, J, additional, Ludka, O, additional, Monhart, Z, additional, Vodnansky, P, additional, Zeman, K, additional, Foldyna, D, additional, Krupicka, J, additional, Podpera, I, additional, Busak, L, additional, Radvan, M, additional, Vomacka, Z, additional, Prosecky, R, additional, Cifkova, R, additional, Durdil, V, additional, Vesely, J, additional, Vaclavik, J, additional, Cervinka, P, additional, Linhart, A, additional, Brabec, T, additional, Miklik, R, additional, Bourhaial, H, additional, Olbrich, H-G, additional, Genth-Zotz, S, additional, Kemala, E, additional, Lemke, B, additional, Böhm, M, additional, Schellong, S, additional, Rieker, W, additional, Heitzer, T, additional, Ince, H, additional, Faghih, M, additional, Birkenfeld, A, additional, Begemann, A, additional, Ghanem, A, additional, Ujeyl, A, additional, von Haehling, S, additional, Dorsel, T, additional, Bauersachs, J, additional, Prull, M, additional, Weidemann, F, additional, Darius, H, additional, Nickenig, G, additional, Wilke, A, additional, Sauter, J, additional, Rauch-Kroehnert, U, additional, Frey, N, additional, Schulze, CP, additional, König, W, additional, Maier, L, additional, Menzel, F, additional, Proskynitopoulos, N, additional, Ebert, H-H, additional, Sarnighausen, H-E, additional, Düngen, H-D, additional, Licka, M, additional, Stellbrink, C, additional, Winkelmann, B, additional, Menck, N, additional, López-Sendón, JL, additional, de la Fuente Galán, L, additional, Delgado Jiménez, JF, additional, Manito Lorite, N, additional, Pérez de Juan Romero, M, additional, Galve Basilio, E, additional, Cereto Castro, F, additional, González Juanatey, JR, additional, Gómez, JJ, additional, Sanmartín Fernández, M, additional, Garcia-Moll Marimon, X, additional, Pascual Figal, D, additional, Bover Freire, R, additional, Bonnefoy Cudraz, E, additional, Jobbe Duval, A, additional, Tomasevic, D, additional, Habib, G, additional, Isnard, R, additional, Picard, F, additional, Khanoyan, P, additional, Dubois-Rande, J-L, additional, Galinier, M, additional, Roubille, F, additional, Alexandre, J, additional, Babuty, D, additional, Delarche, N, additional, Berneau, J-B, additional, Girerd, N, additional, Saxena, M, additional, Rosano, G, additional, Yousef, Z, additional, Clifford, C, additional, Arden, C, additional, Bakhai, A, additional, Boos, C, additional, Jenkins, G, additional, Travill, C, additional, Price, D, additional, Koenyves, L, additional, Lakatos, F, additional, Matoltsy, A, additional, Noori, E, additional, Zilahi, Z, additional, Andrassy, P, additional, Kancz, S, additional, Simon, G, additional, Sydo, T, additional, Vorobcsuk, A, additional, Kiss, RG, additional, Toth, K, additional, Szakal, I, additional, Nagy, L, additional, Barany, T, additional, Nagy, A, additional, Szolnoki, E, additional, Chopra, VK, additional, Mandal, S, additional, Rastogi, V, additional, Shah, B, additional, Mullasari, A, additional, Shankar, J, additional, Mehta, V, additional, Oomman, A, additional, Kaul, U, additional, Komarlu, S, additional, Kahali, D, additional, Bhagwat, A, additional, Vijan, V, additional, Ghaisas, NK, additional, Mehta, A, additional, Kashyap, J, additional, Kothari, Y, additional, TaddeI, S, additional, Scherillo, M, additional, Zacà, V, additional, Genovese, S, additional, Salvioni, A, additional, Fucili, A, additional, Fedele, F, additional, Cosmi, F, additional, Volpe, M, additional, Mazzone, C, additional, Esposito, G, additional, Doi, M, additional, Yamamoto, H, additional, Sakagami, S, additional, Oishi, S, additional, Yasaka, Y, additional, Tsuboi, H, additional, Fujino, Y, additional, Matsuoka, S, additional, Watanabe, Y, additional, Himi, T, additional, Ide, T, additional, Ichikawa, M, additional, Kijima, Y, additional, Koga, T, additional, Yuda, S, additional, Fukui, K, additional, Kubota, T, additional, Manita, M, additional, Fujinaga, H, additional, Matsumura, T, additional, Fukumoto, Y, additional, Kato, R, additional, Kawai, Y, additional, Hiasa, G, additional, Kazatani, Y, additional, Mori, M, additional, Ogimoto, A, additional, Inoko, M, additional, Oguri, M, additional, Kinoshita, M, additional, Okuhara, K, additional, Watanabe, N, additional, Ono, Y, additional, Otomo, K, additional, Sato, Y, additional, Matsunaga, T, additional, Takaishi, A, additional, Miyagi, N, additional, Uehara, H, additional, Takaishi, H, additional, Urata, H, additional, Kataoka, T, additional, Matsubara, H, additional, Matsumoto, T, additional, Suzuki, T, additional, Takahashi, N, additional, Imamaki, M, additional, Yoshitama, T, additional, Saito, T, additional, Sekino, H, additional, Furutani, Y, additional, Koda, M, additional, Shinozaki, T, additional, Hirabayashi, K, additional, Tsunoda, R, additional, Yonezawa, K, additional, Hori, H, additional, Yagi, M, additional, Arikawa, M, additional, Hashizume, T, additional, Ishiki, R, additional, Koizumi, T, additional, Nakayama, K, additional, Taguchi, S, additional, Nanasato, M, additional, Yoshida, Y, additional, Tsujiyama, S, additional, Nakamura, T, additional, Oku, K, additional, Shimizu, M, additional, Suwa, M, additional, Momiyama, Y, additional, Sugiyama, H, additional, Kobayashi, K, additional, Inoue, S, additional, Kadokami, T, additional, Maeno, K, additional, Kawamitsu, K, additional, Maruyama, Y, additional, Nakata, A, additional, Shibata, T, additional, Wada, A, additional, Cho, H-J, additional, Na, JO, additional, Yoo, B-S, additional, Choi, J-O, additional, Hong, SK, additional, Shin, J-H, additional, Cho, M-C, additional, Han, SH, additional, Jeong, J-O, additional, Kim, J-J, additional, Kang, SM, additional, Kim, D-S, additional, Kim, MH, additional, Llamas Esperon, G, additional, Illescas Díaz, J, additional, Fajardo Campos, P, additional, Almeida Alvarado, J, additional, Bazzoni Ruiz, A, additional, Echeverri Rico, J, additional, Lopez Alcocer, I, additional, Valle Molina, L, additional, Hernandez Herrera, C, additional, Calvo Vargas, C, additional, Padilla Padilla, FG, additional, Rodriguez Briones, I, additional, Chuquiure Valenzuela, EJJR, additional, Aguilera Real, ME, additional, Carrillo Calvillo, J, additional, Alpizar Salazar, M, additional, Cervantes Escárcega, JL, additional, Velasco Sanchez, R, additional, Al - Windy, N, additional, van Heerebeek, L, additional, Bellersen, L, additional, Brunner-La Rocca, H-P, additional, Post, J, additional, Linssen, GCM, additional, van de Wetering, M, additional, Peters, R, additional, van Stralen, R, additional, Groutars, R, additional, Smits, P, additional, Yilmaz, A, additional, Kok, WEM, additional, Van der Meer, P, additional, Dijkmans, P, additional, Troquay, R, additional, van Alem, AP, additional, Van de Wal, R, additional, Handoko, L, additional, Westendorp, ICD, additional, van Bergen, PFMM, additional, Rensing, BJWM, additional, Hoogslag, P, additional, Kietselaer, B, additional, Kragten, JA, additional, den Hartog, FR, additional, Alings, A, additional, Danilowicz-Szymanowicz, L, additional, Raczak, G, additional, Piesiewicz, W, additional, Zmuda, W, additional, Kus, W, additional, Podolec, P, additional, Musial, W, additional, Drelich, G, additional, Kania, G, additional, Miekus, P, additional, Mazur, S, additional, Janik, A, additional, Spyra, J, additional, Peruga, J, additional, Balsam, P, additional, Krakowiak, B, additional, Szachniewicz, J, additional, Ginel, M, additional, Grzybowski, J, additional, Chrustowski, W, additional, Wojewoda, P, additional, Kalinka, A, additional, Zurakowski, A, additional, Koc, R, additional, Debinski, M, additional, Fil, W, additional, Kujawiak, M, additional, Forys, J, additional, Kasprzak, M, additional, Krol, M, additional, Michalski, P, additional, Mirek-Bryniarska, E, additional, Radwan, K, additional, Skonieczny, G, additional, Stania, K, additional, Skoczylas, G, additional, Madej, A, additional, Jurowiecki, J, additional, Firek, B, additional, Wozakowska-Kaplon, B, additional, Cymerman, K, additional, Neutel, J, additional, Adams, K, additional, Balfour, P, additional, Deswal, A, additional, Djamson, A, additional, Duncan, P, additional, Hong, M, additional, Murray, C, additional, Rinde-Hoffman, D, additional, Woodhouse, S, additional, MacNevin, R, additional, Rama, B, additional, Broome-Webster, C, additional, Kindsvater, S, additional, Abramov, D, additional, Barettella, M, additional, Pinney, S, additional, Herre, J, additional, Cohen, A, additional, Vora, K, additional, Challappa, K, additional, West, S, additional, Baum, S, additional, Cox, J, additional, Jani, S, additional, Karim, A, additional, Akhtar, A, additional, Quintana, O, additional, Paukman, L, additional, Goldberg, R, additional, Bhatti, Z, additional, Budoff, M, additional, Bush, E, additional, Potler, A, additional, Delgado, R, additional, Ellis, B, additional, Dy, J, additional, Fialkow, J, additional, Sangrigoli, R, additional, Ferdinand, K, additional, East, C, additional, Falkowski, S, additional, Donahoe, S, additional, Ebrahimi, R, additional, Kline, G, additional, Harris, B, additional, Khouzam, R, additional, Jaffrani, N, additional, Jarmukli, N, additional, Kazemi, N, additional, Koren, M, additional, Friedman, K, additional, Herzog, W, additional, Silva Enciso, J, additional, Cheung, D, additional, Grover-McKay, M, additional, Hauptman, P, additional, Mikhalkova, D, additional, Hegde, V, additional, Hodsden, J, additional, Khouri, S, additional, McGrew, F, additional, Littlefield, R, additional, Bradley, P, additional, McLaurin, B, additional, Lupovitch, S, additional, Labin, I, additional, Rao, V, additional, Leithe, M, additional, Lesko, M, additional, Lewis, N, additional, Lombardo, D, additional, Mahal, S, additional, Malhotra, V, additional, Dauber, I, additional, Banerjee, A, additional, Needell, J, additional, Miller, G, additional, Paladino, L, additional, Munuswamy, K, additional, Nanna, M, additional, McMillan, E, additional, Mumma, M, additional, Napoli, M, additional, Nelson, W, additional, O'Brien, T, additional, Adlakha, A, additional, Onwuanyi, A, additional, Serota, H, additional, Schmedtje, J, additional, Paraschos, A, additional, Potu, R, additional, Sai-Sudhakar, C, additional, Saltzberg, M, additional, Sauer, A, additional, Shah, P, additional, Skopicki, H, additional, Bui, H, additional, Carr, K, additional, Stevens, G, additional, Tahirkheli, N, additional, Tallaj, J, additional, Yousuf, K, additional, Trichon, B, additional, Welker, J, additional, Tolerico, P, additional, Vest, A, additional, Vivo, R, additional, Wang, X, additional, Abadier, R, additional, Dunlap, S, additional, Weintraub, N, additional, Malik, A, additional, Kotha, P, additional, Zaha, V, additional, Kim, G, additional, Uriel, N, additional, Greene, T, additional, Salacata, A, additional, Arora, R, additional, Gazmuri, R, additional, Kobayashi, J, additional, Iteld, B, additional, Vijayakrishnan, R, additional, Dab, R, additional, Mirza, Z, additional, Marques, V, additional, Nallasivan, M, additional, Bensimhon, D, additional, Peart, B, additional, Saint-Jacques, H, additional, Barringhaus, K, additional, Contreras, J, additional, Gupta, A, additional, Koneru, S, additional, and Nguyen, V, additional

Published
2022
Full Text
View/download PDF

27. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure

Author

Brugts, J. J., Veenis, J. F., Radhoe, S. P., Linssen, G. C. M., van Gent, M., Borleffs, C. J. W., van Ramshorst, J., van Pol, P., Tukkie, R., Spee, R. F., Emans, M. E., Kok, W., van Halm, V., Handoko, L., Beeres, S. L. M. A., Post, M. C., Boersma, E., Lenzen, M. J., Manintveld, O. C., Koffijberg, H., van Baal, P., Versteegh, M., Smilde, T. D., van Heerebeek, L., Rienstra, M., Mosterd, A., Delnoy, P. P. H., Asselbergs, F. W., Brunner-La Rocca, H. P., and de Boer, R. A.

Subjects
Telemonitoring, e‑Health, CardioMEMS, Heart failure, Therapy, Original Article – Design Study Article, Trial
Abstract

Background Assessing haemodynamic congestion based on filling pressures instead of clinical congestion can be a way to further improve quality of life (QoL) and clinical outcome by intervening before symptoms or weight gain occur in heart failure (HF) patients. The clinical efficacy of remote monitoring of pulmonary artery (PA) pressures (CardioMEMS; Abbott Inc., Atlanta, GA, USA) has been demonstrated in the USA. Currently, the PA sensor is not reimbursed in the European Union as its benefit when applied in addition to standard HF care is unknown in Western European countries, including the Netherlands. Aims To demonstrate the efficacy and cost-effectiveness of haemodynamic PA monitoring in addition to contemporary standard HF care in a high-quality Western European health care system. Methods The current study is a prospective, multi-centre, randomised clinical trial in 340 patients with chronic HF (New York Heart Association functional class III) randomised to HF care including remote monitoring with the CardioMEMS PA sensor or standard HF care alone. Eligible patients have at least one hospitalisation for HF in 12 months before enrolment and will be randomised in a 1:1 ratio. Minimum follow-up will be 1 year. The primary endpoint is the change in QoL as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Secondary endpoints are the number of HF hospital admissions and changes in health status assessed by EQ-5D-5L questionnaire including health care utilisation and formal cost-effectiveness analysis. Conclusion The MONITOR HF trial will evaluate the efficacy and cost-effectiveness of haemodynamic monitoring by CardioMEMS in addition to standard HF care in patients with chronic HF. Clinical Trial Registration number NTR7672. Electronic supplementary material The online version of this article (10.1007/s12471-019-01341-9) contains supplementary material, which is available to authorized users.

Published
2019

31. Understanding needs and expectations of heart failure patients and their caregivers regarding digital health - the PASSION-HF project

Author

Palant, A, primary, Zippel-Schultz, B, additional, Ski, CF, additional, Brandts, J, additional, Eurlings, C, additional, Furtado Da Luz Brzychcyk, E, additional, Hill, L, additional, Dixon, L, additional, Fitzsimons, D, additional, Thompson, D, additional, Mueller-Wieland, D, additional, Schuett, KA, additional, Hoedemakers, T, additional, Brunner La-Rocca, H-P, additional, and Helms, TM, additional

Published
2021
Full Text
View/download PDF

33. Determinants of acceptance of patients with heart failure and their informal caregivers regarding an interactive decision-making system: a qualitative study

Author

Zippel-Schultz, B, Palant, A, Eurlings, C, Ski, CF, Hill, L, Thompson, DR, Fitzsimons, D, Dixon, LJ, Brandts, J, Schuett, KA, de Maesschalck, L, Barrett, M, da Luz, EF, Hoedemakers, T, Helms, TM, Brunner-La Rocca, H-P, Zippel-Schultz, B, Palant, A, Eurlings, C, Ski, CF, Hill, L, Thompson, DR, Fitzsimons, D, Dixon, LJ, Brandts, J, Schuett, KA, de Maesschalck, L, Barrett, M, da Luz, EF, Hoedemakers, T, Helms, TM, and Brunner-La Rocca, H-P

Abstract

OBJECTIVE: Heart failure is a growing challenge to healthcare systems worldwide. Technological solutions have the potential to improve the health of patients and help to reduce costs. Acceptability is a prerequisite for the use and a successful implementation of new disruptive technologies. This qualitative study aimed to explore determinants that influence the acceptance of patients and their informal caregivers regarding a patient-oriented digital decision-making solution-a doctor-at-home system. DESIGN: We applied a semistructured design using an interview guide that was based on a theoretical framework influenced by established acceptance theories. The interviews were analysed using a content analysis. SETTING: A multicentred study in four European countries. PARTICIPANTS: We interviewed 49 patients and 33 of their informal caregivers. Most of the patients were male (76%) and aged between 60 and 69 years (43%). Informal caregivers were mostly female (85%). The majority of patients (55%) suffered from heart failure with mild symptoms. RESULTS: Four main categories emerged from the data: needs and expectations, preferences regarding the care process, perceived risk and trust. Participants expressed clear wishes and expectations regarding a doctor-at-home, especially the need for reassurance and support in the management of heart failure. They were receptive to changes to the current healthcare processes. However, trust was identified as an important basis for acceptance and use. Finally, perceived risk for decision-making errors is a crucial topic in need of attention. CONCLUSION: Patients and informal caregivers see clear benefits of digitalisation in healthcare. They perceive that an interactive decision-making system for patients could empower and enable effective self-care. Our results provide important insights for development processes of patient-centred decision-making systems by identifying facilitators and barriers for acceptance. Further research is need

Published
2021

34. Empagliflozin in heart failure with a preserved ejection fraction

Author

Anker, S, Butler, J, Filippatos, G, Ferreira, J, Bocchi, E, Böhm, M, Brunner-La Rocca, H, Choi, D, Chopra, V, Chuquiure-Valenzuela, E, Giannetti, N, Gomez-Mesa, J, Janssens, S, Januzzi, J, Gonzalez-Juanatey, J, Merkely, B, Nicholls, S, Perrone, S, Piña, I, Ponikowski, P, Senni, M, Sim, D, Spinar, J, Squire, I, Taddei, S, Tsutsui, H, Verma, S, Vinereanu, D, Zhang, J, Carson, P, Lam, C, Marx, N, Zeller, C, Sattar, N, Jamal, W, Schnaidt, S, Schnee, J, Brueckmann, M, Pocock, S, Zannad, F, Packer, M, EMPEROR-Preserved Trial, I, Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Investigators, Anker, S, Butler, J, Filippatos, G, Ferreira, J, Bocchi, E, Böhm, M, Brunner-La Rocca, H, Choi, D, Chopra, V, Chuquiure-Valenzuela, E, Giannetti, N, Gomez-Mesa, J, Janssens, S, Januzzi, J, Gonzalez-Juanatey, J, Merkely, B, Nicholls, S, Perrone, S, Piña, I, Ponikowski, P, Senni, M, Sim, D, Spinar, J, Squire, I, Taddei, S, Tsutsui, H, Verma, S, Vinereanu, D, Zhang, J, Carson, P, Lam, C, Marx, N, Zeller, C, Sattar, N, Jamal, W, Schnaidt, S, Schnee, J, Brueckmann, M, Pocock, S, Zannad, F, Packer, M, EMPEROR-Preserved Trial, I, Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, and EMPEROR-Preserved Trial Investigators

Abstract

BACKGROUND Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

Published
2021

35. Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction:results from the CHECK-HF registry

Author

Uijl, A., Veenis, J. F., Brunner-La Rocca, H. P., van Empel, V., Linssen, G. C.M., Asselbergs, F. W., van der Lee, C., Eurlings, L. W.M., Kragten, H., Al-Windy, N. Y.Y., van der Spank, A., Koudstaal, S., Brugts, J. J., Hoes, A. W., Uijl, A., Veenis, J. F., Brunner-La Rocca, H. P., van Empel, V., Linssen, G. C.M., Asselbergs, F. W., van der Lee, C., Eurlings, L. W.M., Kragten, H., Al-Windy, N. Y.Y., van der Spank, A., Koudstaal, S., Brugts, J. J., and Hoes, A. W.

Abstract

Background: Clinical management of heart failure with preserved ejection fraction (HFpEF) centres on treating comorbidities and is likely to vary between countries. Thus, to provide insight into the current management of HFpEF, studies from multiple countries are required. We evaluated the clinical profiles and current management of patients with HFpEF in the Netherlands. Methods: We included 2153 patients with HFpEF (defined as a left ventricular ejection fraction ≥ 50%) from the CHECK-HF registry, which included patients from 2013 to 2016. Results: Median age was 77 (IQR 15) years, 55% were women and the most frequent comorbidities were hypertension (51%), renal insufficiency (45%) and atrial fibrillation (AF, 38%). Patients between 65 and 80 years and those over 80 years had on average more comorbidities (up to 64% and 74%, respectively, with two or more comorbidities) than patients younger than 65 years (38% with two or more comorbidities, p-value < 0.001). Although no specific drugs are available for HFpEF, treating comorbidities is advised. Beta-blockers were most frequently prescribed (78%), followed by loop diuretics (74%), renin-angiotensin system (RAS) inhibitors (67%) and mineralocorticoid receptor antagonists (MRAs, 39%). Strongest predictors for loop-diuretic use were older age, higher New York Heart Association class and AF. Conclusion: The medical HFpEF profile is determined by the underlying comorbidities, sex and age. Comorbidities are highly prevalent in HFpEF patients, especially in elderly HFpEF patients. Despite the lack of evidence, many HFpEF patients receive regular beta-blockers, RAS inhibitors and MRAs, often for the treatment of comorbidities.

Published
2021

36. Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry

Author

Cardiovasculaire Epi Team 7B, Onderzoek Precision medicine, Team Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Directie Raad van Bestuur, Uijl, A, Veenis, J F, Brunner-La Rocca, H P, van Empel, V, Linssen, G C M, Asselbergs, F W, van der Lee, C, Eurlings, L W M, Kragten, H, Al-Windy, N Y Y, van der Spank, A, Koudstaal, S, Brugts, J J, Hoes, A W, Cardiovasculaire Epi Team 7B, Onderzoek Precision medicine, Team Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Directie Raad van Bestuur, Uijl, A, Veenis, J F, Brunner-La Rocca, H P, van Empel, V, Linssen, G C M, Asselbergs, F W, van der Lee, C, Eurlings, L W M, Kragten, H, Al-Windy, N Y Y, van der Spank, A, Koudstaal, S, Brugts, J J, and Hoes, A W

Published
2021

37. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology

Author

Verplegingswetenschap, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Jaarsma, T, Hill, L, Bayes-Genis, A, Brunner La Rocca, H P, Castiello, T, Čelutkienė, J, Marques-Sule, E, Plymen, C M, Piper, S E, Riegel, B, Rutten, F H, Ben Gal, T, Bauersachs, J, Coats, Ajs, Chioncel, O, Lopatin, Y, Lund, L H, Lainscak, M, Moura, B, Mullens, W, Piepoli, M F, Rosano, G, Seferovic, P, Strömberg, A, Verplegingswetenschap, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Jaarsma, T, Hill, L, Bayes-Genis, A, Brunner La Rocca, H P, Castiello, T, Čelutkienė, J, Marques-Sule, E, Plymen, C M, Piper, S E, Riegel, B, Rutten, F H, Ben Gal, T, Bauersachs, J, Coats, Ajs, Chioncel, O, Lopatin, Y, Lund, L H, Lainscak, M, Moura, B, Mullens, W, Piepoli, M F, Rosano, G, Seferovic, P, and Strömberg, A

Published
2021

42. Nonfocal transient neurological attacks are related to cognitive impairment in patients with heart failure

Author

Oudeman, Eline A., Greving, Jacoba P., Hooghiemstra, Astrid M., Brunner- la Rocca, Hans-Peter, Biessels, Geert Jan, Kappelle, L. Jaap, Daemen, M. J., van Buchem, M. A., van der Geest, R. J., van Osch, M. J. P. J. P., de Roos, A., van der Flier, W. M., van Rossum, A. C., Brunner la Rocca, H. P., Ikram, M. A., Koudstaal, P. J., Niessen, W. J., van Oostenbrugge, R., Bots, M. L., Biessels, G. J., Kappelle, L. J., Paediatric Neurology, Pathology, ACS - Atherosclerosis & ischemic syndromes, ACS - Heart failure & arrhythmias, Epidemiology, Neurology, Radiology & Nuclear Medicine, Amsterdam Neuroscience - Neurodegeneration, APH - Personalized Medicine, APH - Methodology, Epidemiology and Data Science, Cardiology, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: CARIM - R2.02 - Cardiomyopathy, MUMC+: MA Neurologie (3), Klinische Neurowetenschappen, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: CARIM - R3.03 - Cerebral small vessel disease, RS: Carim - H02 Cardiomyopathy, and RS: Carim - B05 Cerebral small vessel disease

Subjects
PARTICIPANTS AGED 24-81, Male, medicine.medical_specialty, Neurology, NORMATIVE DATA, Clinical Neurology, Heart failure, Neuropsychological Tests, Cognitive functioning, DISEASE, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Journal Article, Dementia, Humans, In patient, Cognitive Dysfunction, 030212 general & internal medicine, Cognitive skill, Cognitive impairment, Neuroradiology, ISCHEMIC ATTACK, Aged, RISK, Aged, 80 and over, Original Communication, business.industry, STATEMENT, DEMENTIA, EDUCATION, Middle Aged, medicine.disease, Cross-Sectional Studies, Ischemic Attack, Transient, Cardiology, Etiology, CEREBRAL-BLOOD-FLOW, SEX, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, Transient neurological attacks
Abstract

Introduction Nonfocal transient neurological attacks (TNAs) are associated with an increased risk of future dementia, but it is unclear whether TNAs are also associated with concurrent cognitive impairment. We hypothesized that recent TNAs are related to worse cognitive functioning. We tested our hypothesis in patients with heart failure, as these patients are at risk of cerebral hypoperfusion, which might play a role in the etiology of TNAs. Methods We performed neuropsychological testing in all patients with heart failure enrolled in the Heart Brain Connection study. We assessed global cognition, attention-psychomotor speed, executive functioning, memory and language. All patients were interviewed with a standardized questionnaire on the occurrence of TNAs in the preceding 6 months. We studied associations between TNAs and cognitive functioning with linear and logistic regression analyses, adjusted for age, sex and education. We performed additional analyses in patients without previous stroke or TIA and in patients without brain infarction on MRI. Results Thirty-seven (23%) of 158 patients (mean age 70 years, 67% men) experienced one or more TNAs. Patients with a recent TNA were more likely to be impaired on ≥ 1 cognitive domains than patients without TNAs [41% vs. 18%, adjusted odds ratio 4.6, 95% confidence interval (CI) 1.8–11.8]. Patients with TNAs performed worse than patients without TNAs on global cognition (mean difference in z scores − 0.36, 95% CI − 0.54 to − 0.18), and on the cognitive domains attention-psychomotor speed (mean difference − 0.40, 95% CI − 0.66 to − 0.14), memory (mean difference − 0.57, 95% CI − 0.98 to − 0.15) and language (mean difference − 0.47, 95% CI − 0.79 to − 0.16). These associations were independent of cardiac output and volume of white matter hyperintensities. Subgroup analyses in patients without previous stroke or TIA or brain infarction on MRI (n = 78) yielded comparable results, with the exception of the cognitive domain language, which was no longer different between patients with and without TNAs. Conclusion Among patients with heart failure, TNAs are associated with cognitive impairment, which warrants the need for more clinical awareness of this problem. Electronic supplementary material The online version of this article (10.1007/s00415-019-09376-z) contains supplementary material, which is available to authorized users.

Published
2019
Full Text
View/download PDF

44. A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial

Author

MMB Onderzoek en Onderwijs, Team Medisch, Circulatory Health, Brugts, J. J., Veenis, J. F., Radhoe, S. P., Linssen, G. C.M., van Gent, M., Borleffs, C. J.W., van Ramshorst, J., van Pol, P., Tukkie, R., Spee, R. F., Emans, M. E., Kok, W., van Halm, V., Handoko, M.L., Beeres, S. L.M.A., Post, M. C., Boersma, E., Lenzen, M. J., Manintveld, O. C., Koffijberg, H., van Baal, P., Versteegh, M., Smilde, T. D., van Heerebeek, L., Rienstra, M., Mosterd, A., Delnoy, P. P.H., Asselbergs, F. W., Brunner-La Rocca, H. P., de Boer, R. A., MMB Onderzoek en Onderwijs, Team Medisch, Circulatory Health, Brugts, J. J., Veenis, J. F., Radhoe, S. P., Linssen, G. C.M., van Gent, M., Borleffs, C. J.W., van Ramshorst, J., van Pol, P., Tukkie, R., Spee, R. F., Emans, M. E., Kok, W., van Halm, V., Handoko, M.L., Beeres, S. L.M.A., Post, M. C., Boersma, E., Lenzen, M. J., Manintveld, O. C., Koffijberg, H., van Baal, P., Versteegh, M., Smilde, T. D., van Heerebeek, L., Rienstra, M., Mosterd, A., Delnoy, P. P.H., Asselbergs, F. W., Brunner-La Rocca, H. P., and de Boer, R. A.

Published
2020

45. Cardiovascular and renal outcomes with empagliflozin in heart failure

Author

Packer, M, Anker, S, Butler, J, Filippatos, G, Pocock, S, Carson, P, Januzzi, J, Verma, S, Tsutsui, H, Brueckmann, M, Jamal, W, Kimura, K, Schnee, J, Zeller, C, Cotton, D, Bocchi, E, Böhm, M, Choi, D, Chopra, V, Chuquiure, E, Giannetti, N, Janssens, S, Zhang, J, Gonzalez Juanatey, J, Kaul, S, Brunner-La Rocca, H, Merkely, B, Nicholls, S, Perrone, S, Pina, I, Ponikowski, P, Sattar, N, Senni, M, Seronde, M, Spinar, J, Squire, I, Taddei, S, Wanner, C, Zannad, F, Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, Packer, M, Anker, S, Butler, J, Filippatos, G, Pocock, S, Carson, P, Januzzi, J, Verma, S, Tsutsui, H, Brueckmann, M, Jamal, W, Kimura, K, Schnee, J, Zeller, C, Cotton, D, Bocchi, E, Böhm, M, Choi, D, Chopra, V, Chuquiure, E, Giannetti, N, Janssens, S, Zhang, J, Gonzalez Juanatey, J, Kaul, S, Brunner-La Rocca, H, Merkely, B, Nicholls, S, Perrone, S, Pina, I, Ponikowski, P, Sattar, N, Senni, M, Seronde, M, Spinar, J, Squire, I, Taddei, S, Wanner, C, Zannad, F, Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, and Zannad F

Abstract

BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.

Published
2020

46. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

Author

Anker, S, Butler, J, Filippatos, G, Shahzeb Khan, M, Ferreira, J, Bocchi, E, Böhm, M, Brunner-La Rocca, H, Choi, D, Chopra, V, Chuquiure, E, Giannetti, N, Gomez-Mesa, J, Janssens, S, Januzzi, J, Gonzalez-Juanatey, J, Merkely, B, Nicholls, S, Perrone, S, Piña, I, Ponikowski, P, Senni, M, Seronde, M, Sim, D, Spinar, J, Squire, I, Taddei, S, Tsutsui, H, Verma, S, Vinereanu, D, Zhang, J, Jamal, W, Schnaidt, S, Schnee, J, Brueckmann, M, Pocock, S, Zannad, F, Packer, M, EMPEROR-Preserved Trial Committees and, I, Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Seronde MF, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Committees and Investigators, Anker, S, Butler, J, Filippatos, G, Shahzeb Khan, M, Ferreira, J, Bocchi, E, Böhm, M, Brunner-La Rocca, H, Choi, D, Chopra, V, Chuquiure, E, Giannetti, N, Gomez-Mesa, J, Janssens, S, Januzzi, J, Gonzalez-Juanatey, J, Merkely, B, Nicholls, S, Perrone, S, Piña, I, Ponikowski, P, Senni, M, Seronde, M, Sim, D, Spinar, J, Squire, I, Taddei, S, Tsutsui, H, Verma, S, Vinereanu, D, Zhang, J, Jamal, W, Schnaidt, S, Schnee, J, Brueckmann, M, Pocock, S, Zannad, F, Packer, M, EMPEROR-Preserved Trial Committees and, I, Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Seronde MF, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, and EMPEROR-Preserved Trial Committees and Investigators

Abstract

Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type. natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists a

Published
2020

48. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology

Author

Mullens, W. Damman, K. Harjola, V.-P. Mebazaa, A. Brunner-La Rocca, H.-P. Martens, P. Testani, J.M. Tang, W.H.W. Orso, F. Rossignol, P. Metra, M. Filippatos, G. Seferovic, P.M. Ruschitzka, F. Coats, A.J.

Abstract

The vast majority of acute heart failure episodes are characterized by increasing symptoms and signs of congestion with volume overload. The goal of therapy in those patients is the relief of congestion through achieving a state of euvolaemia, mainly through the use of diuretic therapy. The appropriate use of diuretics however remains challenging, especially when worsening renal function, diuretic resistance and electrolyte disturbances occur. This position paper focuses on the use of diuretics in heart failure with congestion. The manuscript addresses frequently encountered challenges, such as (i) evaluation of congestion and clinical euvolaemia, (ii) assessment of diuretic response/resistance in the treatment of acute heart failure, (iii) an approach towards stepped pharmacologic diuretic strategies, based upon diuretic response, and (iv) management of common electrolyte disturbances. Recommendations are made in line with available guidelines, evidence and expert opinion. © 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results